Life Extension Ventures Files $26.6 Million LifeX Fund II to Back Longevity Startups

Life Extension Ventures II LP has filed $26.6 million for LifeX Fund II US, a deal-by-deal SPV structured under Amol Sarva's investment platform. The August 14 filing marks the second vehicle in the LifeX series — a clear signal that the first fund delivered enough performance to attract fresh LP commitments.

What LifeX invests in

Life Extension Ventures is focused on the longevity sector — companies developing therapeutics, diagnostics, and lifestyle technologies aimed at extending healthy human lifespan. The broader category includes anti-aging drug development, biomarker testing platforms, senolytics, NAD+ and mTOR pathway research, and wearable health monitoring systems. The sector has attracted significant capital in recent years as aging demographics in the US, Japan, and Europe create a structural demand story for longevity interventions.

Who is Amol Sarva

Sarva has a long track record as a founder and investor. He co-founded Virgin Mobile USA and Peek Communications before shifting into venture investing. His career has included positions at Knotel, the flexible workspace company, and broader involvement in the New York technology ecosystem. At Life Extension Ventures, he brings a founder's lens to a scientific sector — a combination that resonates with early-stage longevity startups that need both capital and commercial guidance.

The SPV structure

LifeX Fund II US is structured as a deal-by-deal series rather than a traditional diversified fund. This means each closing within the vehicle is tied to a specific company or round, and LPs can participate selectively rather than committing to a blind pool. At $26.6 million, the vehicle is sized to make multiple meaningful early-stage investments, with typical check sizes in the $1 million to $5 million range at seed and Series A.

What the second fund signals

Sequential fund numbers matter. A Fund II filing confirms that the general partner has built sufficient LP confidence to raise again — typically requiring at least some realized or marked-up returns, continued thesis validation, and a track record of sourcing quality deals. LifeX Fund II entering the market in August 2026 means the longevity sector has active, funded, conviction-driven capital flowing into it, and that Sarva's network is deploying check-writing capacity right now.

What this means for founders

If you are building in longevity, healthspan, diagnostics, or biotech tools for the aging market, the LifeX Fund II filing is a direct invitation to engage. Sector-specific vehicles at this stage are actively sourcing deals. The deal-by-deal structure means individual LPs are evaluating and approving each investment — which creates a higher bar for deals to clear, and also means the GPs who are moving forward on a deal have strong conviction behind it.

Find investors who are actively deploying by creating your pitch listing on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai